Halozyme Therapeutics, Inc. (BMV:HALO)

Halozyme Therapeutics Ratios and Metrics

Market cap in millions MXN. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 28, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Cap	139,046	109,472	87,125	143,000	102,807	107,875
Market Cap Growth	0.20%	25.65%	-39.07%	39.09%	-4.70%	139.34%
Enterprise Value	157,404	126,389	108,755	164,011	103,669	101,031
PE Ratio	13.23	13.94	17.60	39.51	14.68	46.93
Forward PE	8.72	19.22	19.22	19.22	17.89	25.20
PEG Ratio	-	0.41	0.41	0.41	0.46	0.55
PS Ratio	6.26	5.80	5.65	11.65	12.47	21.68
PB Ratio	22.16	16.18	55.91	45.29	28.07	38.41
P/TBV Ratio	429.91	17.01	59.18	47.12	29.97	40.00
P/FCF Ratio	13.64	12.57	12.55	32.68	18.55	109.56
P/OCF Ratio	13.46	12.29	12.06	32.03	18.46	104.61
EV/Sales Ratio	7.20	6.69	7.05	13.36	12.58	20.30
EV/EBITDA Ratio	11.06	10.74	13.85	27.81	19.99	36.83
EV/EBIT Ratio	12.43	12.33	17.33	32.97	20.21	37.66
EV/FCF Ratio	15.44	14.51	15.67	37.49	18.71	102.61
Debt / Equity Ratio	4.54	4.14	17.89	8.79	4.00	0
Debt / EBITDA Ratio	1.97	2.38	3.55	4.75	3.14	2.69
Debt / FCF Ratio	2.79	3.22	4.02	6.40	2.94	7.50
Asset Turnover	0.57	0.53	0.46	0.45	0.53	0.47
Inventory Turnover	1.15	1.18	1.69	1.81	1.42	0.96
Quick Ratio	6.44	6.50	5.07	4.54	7.10	1.11
Current Ratio	8.36	7.80	6.64	5.65	7.91	1.32
Return on Equity (ROE)	160.01%	198.42%	222.07%	110.23%	231.44%	106.33%
Return on Assets (ROA)	26.70%	23.16%	15.27%	14.75%	53.09%	25.14%
Return on Capital (ROIC)	40.72%	33.64%	20.63%	25.58%	117.40%	56.85%
Return on Capital Employed (ROCE)	35.52%	31.11%	20.27%	19.83%	48.16%	45.17%
Earnings Yield	7.56%	7.17%	5.68%	2.53%	6.81%	2.13%
FCF Yield	7.33%	7.96%	7.97%	3.06%	5.39%	0.91%
Buyback Yield / Dilution	0.00%	3.72%	8.42%	2.42%	6.10%	1.49%
Total Shareholder Return	-	3.72%	8.42%	2.42%	6.10%	1.49%

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.